Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 26 publications
18F-Fluorodeoxyglucose-positron emission tomography/computed tomography in Lymphoma.
Journal: PET clinics
Published: August 13, 2026
Fluorodeoxyglucose PET/CT in Nonlymphoma Hematolymphoid Disorders.
Journal: PET clinics
Published: August 10, 2026
Novel Risk Scoring System for Patients with Metastatic Castration Resistant Prostate Cancer Treated with Lutetium-177-PSMA-617.
Journal: The oncologist
Published: June 01, 2026
18F-fluciclovine PET Imaging of Non-PSMA Expressing High-risk Primary Prostate Cancer.
Journal: Clinical nuclear medicine
Published: May 13, 2026
Impact of Bridging Response on Outcomes after CD19 CAR T-Cell Therapy in Large B-Cell Lymphoma.
Journal: Transplantation and cellular therapy
Published: March 13, 2026
68Ga-PSMA PET/CT in biochemically recurrent prostate cancer: association with genomic data.
Journal: European journal of nuclear medicine and molecular imaging
Published: March 02, 2026
Inflammatory biomarkers have a prognostic role in patients with metastatic castration-resistant prostate cancer treated with Lutetium-177-PSMA-617.
Journal: Cancer
Published: September 22, 2025
Clinical outcomes of lutetium-177-PSMA-617 in a racially diverse cohort of patients with metastatic castration-resistant prostate cancer.
Journal: The oncologist
Published: July 16, 2025
Multiprobe PET Imaging: Insignia of Tumor Heterogeneity in a Case of Neuroendocrine Prostate Cancer.
Multiprobe PET Imaging: Insignia of Tumor Heterogeneity in a Case of Neuroendocrine Prostate Cancer.
Journal: Clinical nuclear medicine
Published: June 05, 2025
CAR T-cell therapy response varies by extranodal disease site in large B-cell lymphoma.
Journal: Blood cancer journal
Published: December 24, 2024
Last Updated: 09/26/2026